TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7515453
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of 100 to 250 micrograms/day of G‐CSF, 400 to 800 mg/day of MCZ, and various antibiotics (Group I)
Study: 7515453
Drug: MCZ and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCZ and antibiotics
Study: 22670050
Drug: 2009-2010 seasonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009-2010 seasonal trivalent inactivated influenza vaccine (TIV)
Study: 12734690
Drug: Acetazolamide (ACZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (ACZ) injection 10 min before the second dose of N-isopropyl-[123I] p-iodoamphetamine (IMP)
Study: 8564973
Drug: Carboxyamido‐triazole (CAI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxyamido‐triazole (CAI) administered p.o. daily or every other day
Study: 8564973
Drug: Carboxyamido‐triazole (CAI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxyamido‐triazole (CAI) administered p.o. at 175 mg/m2/day (liquid formulation)
Study: 8564973
Drug: Carboxyamido‐triazole (CAI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carboxyamido‐triazole (CAI) administered p.o. at 330 mg/m2 every‐other‐day (liquid formulation)
Study: 6137227
Drug: Midazolam 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.075 mg kg‐1
Study: 6137227
Drug: Diazepam 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 0.15 mg kg‐1
Study: 17638394
Drug: Dexketoprofen 50mg
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 50mg twice daily
Study: 17638394
Drug: Diclofenac 75mg
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac 75mg twice daily
Study: 12901810
Drug: Protective plastic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective plastic oral guard
Study: 6161788
Drug: Xylene 700
Normalized name: xylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylene 700 mg/m3 + Alcohol 0.8 g/kg
Study: 30706836
Drug: Indapamide retard
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 3)
Study: 21881478
Drug: Etravirine 400
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine 400 mg once daily
Study: 17445476
Drug: Routine medical
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical treatment (oxygen, aminophylline, dexamethasone, and furosemide)
Study: 16624192
Drug: Misoprostol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (50 microg oral, 4 hourly to a maximum of four doses)
Study: 16624192
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three agents (Dinoprostone, Foley catheter, Misoprostol)
Study: 9026379
Drug: Pindolol 30
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol 30 mg, p.o.
Study: 2068470
Drug: Clindamycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin plus aztreonam (900 mg clindamycin + 1 g aztreonam)
Study: 2068470
Drug: Clindamycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin plus cefotaxime (900 mg clindamycin + 1 g cefotaxime)
Study: 25090264
Drug: Add-on sitagliptin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on sitagliptin (50 mg/day)
Study: 22147480
Drug: Ammonia concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammonia concentration 21 mg/m3
Study: 22147480
Drug: Ammonia concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammonia concentration 34 mg/m3
Study: 22147480
Drug: Ammonia concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ammonia concentration 4 mg/m3
Study: 19714601
Drug: Physiotherapist‐guided treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapist‐guided treatment
Study: 9656849
Drug: Experimental agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental agent group
Study: 17589833
Drug: Paroxetine 40
Normalized name: PARoxetine 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 40 mg
Study: 19934804
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (triamcinolone and lidocaine)
Study: 12779069
Drug: Standard eradicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard eradicating treatment
Study: 12779069
Drug: 1-month course
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-month course of empirical treatment
Study: 8308713
Drug: 1-mg tablet
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg tablet given twice daily
Study: 8308713
Drug: 1-mg capsule
Normalized name: haloperidol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg capsule given twice daily
Study: 31573689
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion (beta-adrenergic agonist)
Study: 29802627
Drug: 1% Metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Metformin gel
Study: 27206266
Drug: Mephedrone 200
Normalized name: ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mephedrone 200 mg
Study: 17392542
Drug: Cinnamon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon (1 g/day)
Study: 11863124
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron supplementation (100 mg every 2 weeks or 1 month)
Study: 10424314
Drug: Acarbose (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (100 mg 3 times daily for 1 year)
Study: 16466168
Drug: Western medicinal
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicinal treatment (WM) with additional medication of CHM (modified Huxin Recipe)
Study: 16466168
Drug: Conventional Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Western medicinal treatment (WM)
Study: 12645801
Drug: Interferon-alpha-2b at
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha-2b at 5 MU daily
Study: 18166199
Drug: Hydroxyurea (HU)
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea (HU) at 40 mg/kg/day
Study: 8558634
Drug: Interleukin-2 and
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interleukin-2 and interferon-alpha 2b (4 x 4.8 x 10(6) IU/m.2 interleukin-2 subcutaneously on days 1 and 22, 2 x 4.8 x 10(6) IU/m.2 on days 2 and 23, and 2 x 2.4 x 10(6) IU/m.2 combined with interferon-alpha 2b subcutaneously at 3 x 10(6) IU/m.2 on days 3, 5, 24 and 26, and 6 x 10(6) IU/m.2 3 times weekly for 6 weeks)
Study: 22985134
Drug: 4 weeks
Normalized name: risperiDONE 75 mg/4 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 weeks of treatment with one of 5 different dosing combinations (2 or 3 30-min treatments per week or 1, 2, or 3 60-min treatments per week)
Study: 22985134
Drug: 6 weekly
Normalized name: tobramycin 28 MG inhalation powder 56 Weekly Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 weekly 60-min massages
Study: 16429658
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg daily for 6 weeks
Study: 16429658
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily for 6 weeks
Study: 12630022
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 and steroid administration
Study: 12630022
Drug: Postoperative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative management with steroid, prostaglandin E1, and C-tube drainage
Study: 10226860
Drug: Captopril plus
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril plus diuretics
Study: 10226860
Drug: Digoxin plus
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin plus diuretics
Study: 8764421
Drug: Hydroxyzine (Aterax)
Normalized name: Hydroxizine
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxyzine (Aterax) 1‐2 mg/kg
Study: 1860324
Drug: Standard doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard doses of epinephrine (1 mg iv every 5 mins)
Study: 6354248
Drug: Diversional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diversional occupational therapy
Study: 23975236
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2b (60 μg/m(2)/wk) plus oral ribavirin (15 mg/kg/day)
Study: 20937312
Drug: 60 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 μg YIC therapeutic vaccine
Study: 18582568
Drug: Diclofenac extended
Normalized name: diclofenac Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac extended release (ER) tablet using the conventional dissolution apparatus (USP II)
Study: 18582568
Drug: Plasma concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma concentration versus time profiles after the administration of an ER tablet
Study: 12952230
Drug: EBVD chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBVD chemotherapy
Study: 1815019
Drug: Normal oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal oral hygiene practices (Control)
Study: 27480383
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection
Study: 12115356
Drug: Azoles antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azoles antifungal agents (fluconazole, itraconazole, ketoconazole, miconazole)
Study: 10195512
Drug: i.a. bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.a. bupivacaine (30 mL of 0.25%) + clonidine (1 microg/kg) i.a.
Study: 10195512
Drug: i.a. bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.a. bupivacaine (30 mL of 0.25%)
Study: 10195512
Drug: i.a. bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.a. bupivacaine (30 mL of 0.25%) + subcutaneous clonidine (1 microg/kg)
Study: 10195512
Drug: i.a. bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.a. bupivacaine (30 mL of 0.25%) + epinephrine (5 microg/mL)
Study: 2157640
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (intravenous plus oral)
Study: 2157640
Drug: Cisplatin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (70 mg/m2)
Study: 25541155
Drug: Docetaxel treatment
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel treatment
Study: 31027929
Drug: PHiD-CV10 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV10 vaccine
Study: 31027929
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (hepatitis A or B vaccine)
Study: 17692723
Drug: Tretinoin gel
Normalized name: Tretinoin Gel
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin gel microspheres 0.04%
Study: 11697427
Drug: Multidisciplinary behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidisciplinary behavioural treatment
Study: 9803573
Drug: Self-help programme
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-help programme for climacteric and menopause, consisting of 10 weekly hour-long sessions including body movement exercises, relaxation, and group discussions.
Study: 2148360
Drug: High-dosage phenobarbital
Normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosage phenobarbital and cefotaxime
Study: 28779928
Drug: SilAtro‐5‐90 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: SilAtro‐5‐90 in addition to standard symptomatic treatment
Study: 21739700
Drug: Electroacupuncture compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture compound anesthesia (Sibai ST 2, Xiaguan ST 7, Hegu LI 4, Zhigou TE 6 on left side; routine local anesthesia on right side)
Study: 21739700
Drug: Electroacupuncture compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture compound anesthesia
Study: 12495686
Drug: PMX-F treatment
Normalized name: F-15599
DrugBank: F-15599 (DB16936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PMX-F treatment (N=15)
Study: 12495686
Drug: Teicoplanin treatment
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin treatment (N=15)
Study: 12495686
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (N=10)
Study: 1859070
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 4% lidocaine to the oral mucosa
Study: 30415298
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg once daily with theophylline 100 mg twice daily (Group I)
Study: 30415298
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg once daily (Group II)
Study: 1662119
Drug: Didemnin B
Normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didemnin B at doses ranging from 3.47 to 9.1 mg/m2
Study: 1662119
Drug: Didemnin B
Normalized name: Dehydrodidemnin B
DrugBank: Plitidepsin (DB04977)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didemnin B at a recommended dose of 6.3 mg/m2
Study: 1662119
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of antiemetics including dexamethasone
Study: 7073046
Drug: Oxacillin 500
Normalized name: oxacillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxacillin 500 mg QID x 5 days
Study: 30830377
Drug: L-aspartic acid
Normalized name: L-Aspartic Acid
DrugBank: Aspartic acid (DB00128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-aspartic acid
Study: 26884590
Drug: Sorafenib +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib + Everolimus (S + E) 800 mg + 5 mg daily
Study: 21988149
Drug: Fenoprofen Calcium
Normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoprofen Calcium (200 mg) in three-layered gum tablet (1800 mg)
Study: 21988149
Drug: Lyophilized ternary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized ternary complex containing 100 mg of Fn with PVP K(25)
Study: 21988149
Drug: Fenoprofen Calcium
Normalized name: Fenoprofen Calcium
DrugBank: Fenoprofen (DB00573)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoprofen Calcium (100 mg) in chewing gum
Study: 21988149
Drug: Selected gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selected gum tablet
Study: 15892043
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus docetaxel (1250 mg/m2 twice daily on Days 1-14 plus docetaxel 75 mg/m2 on Day 1)
Study: 15892043
Drug: Docetaxel alone
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel alone (100 mg/m2 on Day 1)
Study: 11845111
Drug: Non-hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-hormone replacement therapy (nonHRT) alternatives
Study: 24726159
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution applied for 15 seconds (Control)
Study: 23264316
Drug: Oxymorphone ER
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxymorphone ER (20 mg)
Study: 12376581
Drug: rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (8 mg/day, 2 divided doses)
Study: 9456163
Drug: Isradipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (calcium channel blocker)
Study: 9456163
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Isradipine and Placebo)
Study: 30910569
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (10 minutes to the quadriceps)
Study: 16480565
Drug: Cognitive-behaviour therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behaviour therapy group programme for social phobia (10 sessions)
Study: 17561562
Drug: Topical betamethasone
Normalized name: betamethasone Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical betamethasone 0.1%
Study: 27015572
Drug: Topical nepafenac
Normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical nepafenac 0.1%
Study: 31638843
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no anti-inflammatory agent)
Study: 10974130
Drug: Indomethacin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (0.2 mg/kg, given at 12-hour intervals)
Study: 10974130
Drug: Ibuprofen (first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (first dose of 10 mg/kg, followed by two doses of 5 mg/kg at 24-hour intervals)
Study: 10974130
Drug: Indomethacin and
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indomethacin and Ibuprofen
Study: 8781823
Drug: Bamiphylline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamiphylline (5 mg.kg‐1)
Study: 8331207
Drug: Intravenous ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ceftazidime 1 g
Study: 8331207
Drug: Intraperitoneal ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal ceftazidime 1 g
Study: 2867861
Drug: Almitrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almitrine (3 mg/kg single dose, oral)
Study: 30400221
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (20 g for 6 days followed by 2 g until the end of the study)
Study: 21985440
Drug: Prefabricated oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prefabricated oral appliance (R)
Study: 21358487
Drug: Individually administered
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually administered physical therapy (IAPT)
Study: 17183729
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg)
Study: 12860866
Drug: Nisoldipine 40
Normalized name: nisoldipine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisoldipine 40 mg once daily
Study: 9273229
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO) administered subcutaneously at a dose of 2000 U twice weekly (group II)
Study: 30341345
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF), oral dose 300 mg/day, initiated at 24 weeks of gestation and continued to 4 weeks after delivery
Study: 30341345
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TDF treatment)
Study: 25176317
Drug: Clinic-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic-based intervention including educational, organizational, and behavioral components administered by trained lay personnel.
Study: 22574965
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light (IPL) and fractional photothermolysis (FP) combination treatment
Study: 20860133
Drug: Simo Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simo Decoction Oral Liquid
Study: 7801949
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of i.v. nitroglycerin (150 micrograms) and metoclopramide (20‐mg bolus)
Study: 3082230
Drug: praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: praziquantel (40 mg/kg)
Study: 91436
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy consisting of bleomycin, vinblastine, Adriamycin, and cis‐dichlorodiammineplatinum(II)
Study: 23507228
Drug: Blueberries (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blueberries (300 g)
Study: 15152896
Drug: Diphenhydramine 50
Normalized name: diphenhydrAMINE 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine 50 mg (active control)
Study: 3073625
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg x 2 for 5 days)
Study: 3073625
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1.5 g x 3 for 3 days, 1 g x 2 days 4 and 5)
Study: 25167960
Drug: 1.1 mg
Normalized name: menthol 1.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 mg folic acid
Study: 12702070
Drug: PUVA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUVA and topical calcipotriol
Study: 1397915
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium cleansing solution
Study: 11540865
Drug: d-fenfluramine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-fenfluramine (15 mg p.o., twice daily)